X

Trial Profile

A clinical study of STP125G for the treatment of cardiovascular disease indications

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 17 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs STP 125G (Primary)
Indications Hypertriglyceridaemia
Focus Adverse reactions

Most Recent Events

12 Jul 2024 According to a Sirnaomics media release, safety and efficacy results from non-human primate (NHP) studies strongly support for an IND filing with the U.S. FDA for initiating a Phase I clinical study of STP125G for cardiovascular disease indications.
02 Apr 2024 New trial record
28 Mar 2024 According to a Sirnaomics media release, the company plans to file a U.S. IND for STP144G from the GalAhead delivery platform in 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com